JW Pharmaceutical·VORONOI, Joint develpoment of targeting STAT3 in anticancer field

2021-11-09T10:00:40+00:00

JW Pharmaceutical·VORONOI, Joint develpoment of targeting STAT3 in anticancer field - mk.co.kr On December 2, JW Pharmaceutical inked a deal with Korean biotech startup Voronoi to develop next-generation innovative new drugs. It plans to develop a next-generation innovative new drug with global competitiveness by combining JW Pharmaceutical's small molecule anticancer drug candidate of targeting STAT3 with Voronoi's protein decomposition technology 'Protein Degrader(PROTAC; Proteolysis-targeting chimera)'. 기사 전문보기

JW Pharmaceutical·VORONOI, Joint develpoment of targeting STAT3 in anticancer field2021-11-09T10:00:40+00:00

Sangjin Lee

2020-10-23T14:21:54+00:00

Bank of Korea Seoul National University, Economics, B.A. Sangjin Lee / Human Resources we strive to set up a proper KPI and continuously improve the foundation for fair evaluation of the passions and efforts of all colleagues in respective positions, which eventually leads to Voronoi’s culture. "Prior to joining Voronoi, I have served for the Bank of Korea over 10 years in various areas including business management, foreign exchange reserves management strategy, performance evaluation system, and macroeconomic analysis and forecast. During the time at the Bank of Korea, it was a meaningful experience to work with global investment banks in New York, USA, as I had a chance to look at how the performance-oriented and open organizational culture, which is different from the seniority-based Korean corporate organization, actually works. At Voronoi, I am responsible for establishing KPIs and organization operation. Voronoi is a young company with diverse range of professionals with outstanding careers ranging from business development, IPR, legal, strategy, patents, management support, AI, and clinical development, as well as key science areas related to new drug development such as new drugs synthesis and biotechnology. The value spectrum of each and every individual is as diverse as our specializations towards growth. With this in mind, we strive to set up a proper KPI and continuously improve the foundation for fair evaluation of the passions and efforts of all colleagues in respective positions, which eventually leads to Voronoi’s culture. " Bank of Korea Seoul National University, Economics, B.A. Sangjin Lee / Human Resources we strive to set up a proper KPI and continuously improve the foundation for fair evaluation of the passions and efforts of all colleagues in respective positions, which eventually leads to Voronoi’s culture. "Prior to joining Voronoi, I have served for the Bank of Korea over 10 years in various areas including business management, foreign exchange reserves management strategy, performance evaluation system, and macroeconomic analysis and forecast. During the time at the Bank of Korea, it was a meaningful experience to work with global investment banks in New York, USA, as I had a chance to look at how the performance-oriented and open organizational culture, which is different from the seniority-based Korean corporate organization, actually works. At Voronoi, I am responsible for establishing KPIs and organization operation. Voronoi is a young company with diverse range of professionals with outstanding careers ranging from business development, IPR, legal, strategy, patents, management support, AI, and clinical development, as well as key science areas related to new drug development such as new drugs synthesis and biotechnology. The value spectrum of each and every individual is as diverse as our specializations towards growth. With this in mind, we strive to set up a proper KPI and continuously improve the foundation for fair evaluation of the passions and efforts of all colleagues in respective positions, which eventually leads to Voronoi’s culture. "

Sangjin Lee2020-10-23T14:21:54+00:00

Young Mo Kang, MD, PhD

2021-10-28T14:30:31+00:00

Young Mo Kang, MD, PhD Department of Internal Medicine, Kyungpook National University School of Medicine, Korea Dr. Kang is currently professor in Kyungpook National School of Medicine, Department of Internal Medicine and Biochemistry & Cell Biology. Dr. Kang has special expertise in Rheumatology area. Dr. Kang’s educational background goes back to 1986, when he achieved his B.S. degree in Medicine in Kyungpook National University. He then achieved his PhD degree in the same school in year 1996. He then joined as an instructor in department of internal medicine in Dongguk University School of Medicine. He then became professor in Kyungpook National University, Department of Internal Medicine in 1997 and since then he is still serving his role as a professor in the same school. In 1991, he served his post-doctoral fellowship in Mayo Clinic in USA where he focused the research of Rheumatology in Department of Medicine and Immunology. Dr. Kang also served as a chairman of Department of Internal Medicine from 2014 to 2016. Dr. Kang is currently CEO of Preclina Inc. as well. Dr. Kang is currently a member of American Association of Immunologists, American Society of Matrix Biology, Asian Pacific League of Rheumatologists, Korean College of Rheumatology and an International Fellow Member of American College of Rheumatology. He has also been a steering committee of The Korean Study Group of Synovitis Research since 2007 and editor-in-chief of World Journal of Rheumatology since 2015. Dr. Kang was a principal investigator of clinical trials of Tofacitinib (Pfizer) and Filgotinib (Galapagos). Young Mo Kang, MD, PhD Department of Internal Medicine, Kyungpook National University School of Medicine, Korea Dr. Kang is currently professor in Kyungpook National School of Medicine, Department of Internal Medicine and Biochemistry & Cell Biology. Dr. Kang has special expertise in Rheumatology area. Dr. Kang’s educational background goes back to 1986, when he achieved his B.S. degree in Medicine in Kyungpook National University. He then achieved his PhD degree in the same school in year 1996. He then joined as an instructor in department of internal medicine in Dongguk University School of Medicine. He then became professor in Kyungpook National University, Department of Internal Medicine in 1997 and since then he is still serving his role as a professor in the same school. In 1991, he served his post-doctoral fellowship in Mayo Clinic in USA where he focused the research of Rheumatology in Department of Medicine and Immunology. Dr. Kang also served as a chairman of Department of Internal Medicine from 2014 to 2016. Dr. Kang is currently CEO of Preclina Inc. as well. Dr. Kang is currently a member of American Association of Immunologists, American Society of Matrix Biology, Asian Pacific League of Rheumatologists, Korean College of Rheumatology and an International Fellow Member of American College of Rheumatology. He has also been a steering committee of The Korean Study Group of Synovitis Research since 2007 and editor-in-chief of World Journal of Rheumatology since 2015.

Young Mo Kang, MD, PhD2021-10-28T14:30:31+00:00

Dana-Farber Cancer Institute grants exclusive right of protein degradation patent to Voronoi – Asia Biz

2019-12-30T18:22:31+00:00

Dana-Farber Cancer Institute grants exclusive right of protein degradation patent to Voronoi-AsiaBiz View the update

Dana-Farber Cancer Institute grants exclusive right of protein degradation patent to Voronoi – Asia Biz2019-12-30T18:22:31+00:00

Lilliun

2019-08-17T20:58:32+00:00

Scientific Advisor: Lillian L. Siu, M.D. BMO Chair in Precision Genomics Professor of Medicine, Princess Margaret Cancer Centre, Toronto, Canada Dr. Siu is a senior medical oncologist at Princess Margaret Cancer Centre since 1998, and has been a Professor of Medicine at the University of Toronto since 2009. She is the Director of the Phase I Program and Co-Director of the Bras and Family Drug Development Program at Princess Margaret Cancer Centre, and holds the BMO Chair in Precision Genomics (2016-2026).  She is also the Clinical Lead for the Tumor Immunotherapy Program at Princess Margaret Cancer Centre. Dr. Siu served on the Board of Directors for the American Society of Clinical Oncology (ASCO) for a four-year term (2012-2016). She also served as a member of the Nomination Committee for the American Association for Cancer Research (AACR) (2014-2016). She currently serves on the AACR Board of Directors for a three-year term (2017-2020). Dr. Siu’s major research focus is in the area of new anticancer drug development, particularly with respect to phase I trials and head and neck malignancies.  She is the Principal Investigator of a phase I cooperative agreement UM1 award (2014-2019) sponsored by the United States National Cancer Institute. In addition to her active research in early phase clinical trials, she has been leading genomics initiatives and immuno-oncology trials at the Princess Margaret Cancer Centre. Together, the three programs of drug development, cancer genomics and tumor immunotherapy form a triad of synergy that supports the institution’s core vision to deliver precision cancer medicine. Internationally, Dr. Siu was the recipient of the US NCI Michaele C. Christian Award in Oncology Drug Development in 2010.  Locally, she was awarded the University of Toronto Department of Medicine Eaton Scholar Researcher in 2016.  She was the ASCO Conquer Cancer Foundation Grants Selection Committee Chair in 2009-10. She was Chairperson of the AACR Education Committee, Co-Chairperson of the Scientific Committee for the 2012 Annual Meeting and Co-Chairperson for the Clinical Trials Committee 2015-2017. Dr. Siu has published over 300 peer-reviewed manuscripts, and she is currently a scientific editor for Cancer Discovery and is on the editorial board for JAMA Oncology. Lillian L. Siu, M.D. BMO Chair in Precision Genomics Professor of Medicine, Princess Margaret Cancer Centre, Toronto, Canada Dr. Siu is a senior medical oncologist at Princess Margaret Cancer Centre since 1998, and has been a Professor of Medicine at the University of Toronto since 2009. She is the Director of the Phase I Program and Co-Director of the Bras and Family Drug Development Program at Princess Margaret Cancer Centre, and holds the BMO Chair in Precision Genomics (2016-2026).  She is also the Clinical Lead for the Tumor Immunotherapy Program at Princess Margaret Cancer Centre. Dr. Siu served on the Board of Directors for the American Society of Clinical Oncology (ASCO) for a four-year term (2012-2016). She also served as a member of the Nomination Committee for the American Association for Cancer

Lilliun2019-08-17T20:58:32+00:00

(Korean) 일터로서의 보로노이

2023-04-17T11:20:21+00:00

Seoul National University, B.S. Fast growth "For Voronoi, it only takes 1.5 years to develop a new drug candidate." For Voronoi, it only takes 1.5 years to develop a new drug candidate while it usually takes 4.5 years in the industry average. The speed is exceptionally high. The reason for this high speed is because we, Voronoi, have many talents and professional experts who majored in molecular modeling, medicinal chemistry, and kinase inhibitor development. Each of them are Dr. Kim, Dr. Choi, and Dr. Gray. They all have previous experience of creating and developing novel small molecule drugs and out-licensing them to global leading pharmaceutical companies. I am proud that I can be also part of this team and the company, learning from them. There are much more to catch up. My job definitely requires fast learning speed. Collaboration "Effective partnership" Voronoi is collaborating with Dana-Farber Cancer Institute, Yonsei University Medical School, Korea Brain Research Institute, National Cancer Center, etc. We also have Dr. Janne of Harvard Medical School as our scientific advisory board for our lung cancer pipeline. We frequently have a discussion with our partners and advisors. Collaboration does not only apply to external partners, but also to internal teams. Voronoi pursue open-minded and respecting working culture and we aim to have effective discussion between teams and divisions. If you can lead effective meetings with bright energy, you will find yourself so fit into our culture. Work & Life balance "Flexible and Efficient" Voronoi pursues flexible and efficient working culture. You don’t need to sit on the chair only to show your presence. Suppose you have personal appointments and want to leave office early. You can always do so if you are done with your work. We give ownership and responsibility to each employee with huge trust. You can find flexible working culture here in Voronoi.

(Korean) 일터로서의 보로노이2023-04-17T11:20:21+00:00
032-830-4855 / contact@voronoi.io
S 18th F,Songdogwahak-ro 32(ITcenter), Yeonsu-gu, Incheon, Republic of Korea
Copyrightⓒ Voronoi All Rights reserved.
KoreaUSA